Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction.

A prospective study evaluated the comparative haemodynamic effects of three Class I antiarrhythmics (lignocaine Class 1B, disopyramide Class 1A and flecainide Class 1C) in 30 patients with uncomplicated acute myocardial infarction. Three groups, each of 10 patients, were allocated to lignocaine (Group I) 1.5 mg kg-1 i.v. loading dose over 10 min followed by infusion at 3 mg kg-1 h-1, disopyramide (Group II) or flecainide (Group III), both administered as a 1.0 mg kg-1 i.v. loading bolus over 10 min followed by a 1.6 mg kg-1 h-1 infusion for 120 min. The plasma levels of each drug were in the described therapeutic range. Lignocaine decreased cardiac index (-0.3 l min-1 m-2 (9%); P less than 0.05) and stroke volume index (-5 ml m-2 (11%); P less than 0.01). Systemic blood pressure, heart rate and systemic vascular resistance index were unchanged. There was a small increase (+3 mm Hg (30%); P less than 0.01) in pulmonary artery occluded pressure (PAOP). Both disopyramide and flecainide increased systemic blood pressure; the maximum increases for mean blood pressure were +10 mm Hg (11%) and +4 mm Hg (4%) respectively. Both drugs reduced cardiac index (-0.5 l min-1 m-2 (16%): -0.4 l min-1 m-2 (11%)) and stroke volume index (-11 ml m-2 (25%): -5 ml m-2 (11%)). There were increases in heart rate (+13: +5 beats min-1) pulmonary artery occluded pressure (+2: +3 mm Hg) and systemic vascular resistance index (+696: +275 dyn s cm-5 m2).(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  B. Silke,et al.  Hemodynamic dose‐response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation , 1985, Clinical pharmacology and therapeutics.

[2]  J. Johnson,et al.  Quantitation of flecainide acetate, a new antiarrhythmic agent, in biological fluids by gas chromatography with electron-capture detection. , 1984, Journal of pharmaceutical sciences.

[3]  B. Singh,et al.  Effects of flecainide on ventricular function: clinical and experimental correlations. , 1984, The American journal of cardiology.

[4]  J. Anderson,et al.  A proposal for the clinical use of flecainide. , 1984, The American journal of cardiology.

[5]  R. Norris,et al.  Intravenous Disopyramide in Acute Myocardial Infarction: A Haemodynamic and Pharmacokinetic Study , 1984, Journal of cardiovascular pharmacology.

[6]  P. Serruys,et al.  The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease. , 1983, British journal of clinical pharmacology.

[7]  V. Legrand,et al.  Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818), in coronary heart disease. , 1983, The American journal of cardiology.

[8]  G. Sutton,et al.  A long-term prevention study with oxprenolol in coronary heart disease. , 1982, The New England journal of medicine.

[9]  L. Griffith,et al.  Suppression of complex ventricular arrhythmias by oral flecainide , 1982, Clinical pharmacology and therapeutics.

[10]  A. Camm,et al.  Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. , 1982, British heart journal.

[11]  R. Asinger,et al.  Suppression of Ventricular Ectopic Depolarizations by Flecainide Acetate, A New Antiarrhythmic Agent , 1982, Circulation.

[12]  D. Roden,et al.  Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. , 1981, The American journal of cardiology.

[13]  B. Pitt,et al.  Oral flecainide acetate for the treatment of ventricular arrhythmias. , 1981, The New England journal of medicine.

[14]  Mike W. S. Martin The management of arrhythmias. , 2008, Medical times.

[15]  R. Schröder,et al.  Effects of disopyramide on systemic and coronary hemodynamics and myocardial metabolism in patients with coronary artery disease: comparison with lidocaine. , 1980, The American journal of cardiology.

[16]  R. Mccomb,et al.  Simultaneous liquid-chromatographic determination of three antiarrhythmic drugs: disopyramide, lidocaine, and quinidine. , 1980, Clinical Chemistry.

[17]  J. Koch-weser Drug therapy: bretylium. , 1979, The New England journal of medicine.

[18]  J. Vogt,et al.  [The comparative hemodynamic effects of antiarrhythmic drugs in acute myocardial infarction (comparison of propafenone and lidocaine) (author's transl)]. , 1978, Zeitschrift fur Kardiologie.

[19]  G. Rosenhamer,et al.  Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia. , 2009, Acta medica Scandinavica.

[20]  P. Armstrong,et al.  Comparative effects of lidocaine and procainamide on acutely impaired hemodynamics. , 1976, The American journal of medicine.

[21]  A. Niarchos Disopyramide: serum level and arrhythmia conversion. , 1976, American heart journal.

[22]  R. Miller,et al.  Hemodynamic effects of procainamide in patients with acute myocardial infarction and comparison with lidocaine. , 1973, The American journal of medicine.

[23]  K. Rosen,et al.  Lidocaine infusion in acute myocardial infarction. Effects on left ventricular function. , 1971, Archives of internal medicine.

[24]  J. Frieden,et al.  Cardiovascular effects of infusion of lidocaine on patients with heart disease. , 1969, The American journal of cardiology.

[25]  H. Blackburn,et al.  Cardiovascular survey methods. , 1969, Monograph series. World Health Organization.

[26]  John F. Williams,et al.  Hemodynamic Effects of Lidocaine in Patients with Heart Disease , 1968, Circulation.